Myozyme® (alglucosidase alfa) ( DrugBank: Alglucosidase alfa )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
256	筋型糖原病	2

256. 筋型糖原病

---

臨床試験数 : 180 /  薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00701701 (ClinicalTrials.gov)	December 14, 2008	17/6/2008	Immune Tolerance Induction Study	An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme	Pompe Disease;Glycogen Storage Disease Type II (GSD-II);Glycogenesis 2 Acid Maltase Deficiency	Biological: Myozyme® (alglucosidase alfa)	Genzyme, a Sanofi Company	NULL	Terminated	1 Month	N/A	All	4	Phase 4	United States;Israel;Canada
2	EUCTR2015-000582-31-Outside-EU/EEA (EUCTR)		15/04/2015	An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen	An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen	Pompe disease (acid alpha-glucosidase deficiency) MedDRA version: 17.1;Level: LLT;Classification code 10036143;Term: Pompe's disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Myozyme 50 mg powder for concentrate for solution for infusion INN or Proposed INN: ALGLUCOSIDASE ALFA	Genzyme Corporation Inc	NULL	NA			Female: yes Male: yes	14		United States;Australia;Canada